Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry

Documenti analoghi

• Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
  di: Kuemmerle-Deschner, J, et al.
  Pubblicazione: (2015)
• Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
  di: Tilson, Hugh, et al.
  Pubblicazione: (2013)
• Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians
  di: Kuemmerle-Deschner, Jasmin B., et al.
  Pubblicazione: (2013)
• β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics
  di: Kuemmerle-Deschner, J, et al.
  Pubblicazione: (2011)
• Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome
  di: Kuemmerle-Deschner, Jasmin Beate, et al.
  Pubblicazione: (2020)